Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
November 09 2022 - 4:01PM
Business Wire
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage
biotechnology company discovering and developing breakthrough
treatments for immune-mediated and oncologic disorders, today
announced members of the executive team will participate in two
upcoming investor conferences in November.
Presentation Details:
Event: Jefferies London Healthcare Conference
Location: London, UK Date/Time: Wednesday, November
16, 2022, at 8:35 AM GMT Presenter: Noreen Roth Henig, M.D.,
Chief Medical Officer Format: Fireside Chat
Event: Evercore ISI 5th Annual HealthCONx Conference
Location: Boston, MA Date/Time: Wednesday, November
30, 2022, at 12:10 PM ET Presenters: John Fowler,
Co-Founder, Chief Executive Officer Format: Fireside
Chat
Webcasts from the presentations will be available on the “Events
& Presentations” section of the Company’s website at
www.kezarlifesciences.com. Following the events, archived webcasts
will be available on the Kezar website for 90 days.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical
company discovering and developing breakthrough treatments for
immune-mediated and oncologic disorders. The company is pioneering
first-in-class, small-molecule therapies that harness master
regulators of cellular function to inhibit multiple drivers of
disease via single, powerful targets. Zetomipzomib, its lead
development asset, is a selective immunoproteasome inhibitor being
evaluated in a Phase 2 clinical trial in lupus nephritis. This
product candidate also has the potential to address multiple
chronic immune-mediated diseases. KZR-261 is the first anti-cancer
clinical candidate from the company’s platform targeting the Sec61
translocon and the protein secretion pathway. An open-label
dose-escalation Phase 1 clinical trial of KZR-261 to assess safety,
tolerability and preliminary tumor activity in solid tumors is
underway. For more information, visit
www.kezarlifesciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221109005819/en/
Investor Contact: Gitanjali Jain Vice President, Investor
Relations and External Affairs gjain@kezarbio.com
Media Contact: Julia Deutsch Solebury Strategic
Communications jdeutsch@soleburystrat.com
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From Sep 2023 to Sep 2024